Vonk, J
Voskuil, FJ
de Wit, JG
Heeman, WT
Nagengast, WB
van Dam, GM
Feijen, RA
Korsten-Meijer, AGW
van der Vegt, B
Witjes, MJH
Article History
Received: 27 May 2021
Accepted: 17 September 2021
First Online: 5 November 2021
Declarations
:
: The study protocol was approved by the institution’s medical ethics committee, and the trial was performed in accordance with the principles of Good Clinical Practice guidelines and the Declaration of Helsinki.
: Signed written informed consent was obtained from all patients included in the study.
: GMvD is CEO, founder, and shareholder of TRACER Europe BV/AxelaRx. BvdV is member of the Scientific Advisory Board of Visiopharm for which compensation is received by the UMCG. The other authors declare no competing interests.